Introduction: Although the implementation of transradial intervention (TRI) has increased over the last few years, there are limited data on the impact of TRI on efficacy and safety in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). We sought to compare one-year clinical outcomes and bleeding complications of TRI with those of transfemoral intervention (TFI) in patients with NSTE-ACS.
AFRICA
Risks related to PCI comprise ischaemic complications, including cardiac death (CD), myocardial infarction (MI), stent thrombosis and stroke, as well as vascular complications such as bleeding. 1 Bleeding complications are associated with subsequent morbidity and mortality rates, 30 to 70% of which are related to the vascular access site. 4, 5 A recent meta-analysis of 76 studies involving a total of 761 919 patients concluded that transradial intervention (TRI) was associated with a 78% reduction in rate of bleeding and 80% reduction in transfusion rates, regardless of the clinical indication for PCI, compared with transfemoral intervention (TFI). 6 This is consistent with results from the largest randomised trial done to date. 5 However, the clinical outcomes of TRI varied according to the clinical settings of the studies, including the inclusion criteria.
Recent large, randomised trials have demonstrated that TRI reduced mortality rates in patients with ST-segment elevation myocardial infarction (STEMI). 5, 7 By contrast, for treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS), the clinical benefits of TRI remain less well defined. Although there have been a few studies comparing results between TRI and TFI in patients with NSTE-ACS, the only available data were derived from a subgroup analysis or post hoc analysis of those studies. 5, 8, 9 Therefore our main objective was to compare one-year clinical outcomes and bleeding complications of TRI with those of TFI in patients with NSTE-ACS, using data from the Korean TRI registry (KOTRI registry).
Methods
The KOTRI registry was an observational cohort over six months (February to July 2014) in 20 centres in Korea. However, due to different processing times for institutional review board (IRB) approval at the participating centres, the entire study population was enrolled from May 2012 to January 2015. 10 All patients were included if they had NSTE-ACS, non-STsegment elevation myocardial infarction (NSTEMI) or unstable angina, an invasive approach was proposed, and the interventional cardiologist was willing to proceed with radial access. Patients were required to have intact dual circulation of the hand, as assessed by an Allen's test, and radial and femoral artery access were based on the reported final access site.
At the time of admission, patients gave written consent for the storing of their information in the hospital's medical records. This study was approved by the IRB of Soonchunhyang University Hospital, Seoul, Korea, as well as by all participating centres, and was conducted according to the principals of the Declaration of Helsinki.
The primary efficacy endpoint of this study was major adverse cardiovascular events (MACE), defined as a composite of CD, non-fatal MI and repeat revascularisation (RR). The secondary efficacy endpoints included individual components of MACE. All deaths were considered to have a cardiac cause unless a non-cardiac origin was definitively documented. MI was defined according to the recommendations of the ESC/ACCF/AHA/ WHF task force. 11 RR was defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel.
Bleeding complications were recorded during admission and defined according to the Bleeding Academic Research Consortium (BARC) criteria. 12 Major bleeding was defined as BARC type 2 or above (any overt, actionable sign of haemorrhage that meets at least one of the following criteria: (1) requiring non-surgical, medical intervention by a healthcare professional, (2) leading to hospitalisation or increased level of care, or (3) prompting evaluation). Minor bleeding was defined as BARC type 1 (bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalisation or treatment by a healthcare professional).
All patients were pre-treated with aspirin and a platelet P2Y12 inhibitor. The selection of angioplasty equipment, including the choice of drug-eluting stents (DES) and the use of glycoprotein IIb/IIIa inhibitors during the procedure were left to the operator's discretion, as was the use of vascular closure devices. After the procedure, all patients received aspirin indefinitely and a P2Y12 inhibitor for at least 12 months.
After the index PCI, one-, six-, nine-and 12-month follow ups were recommended. Clinical, angiographic, procedural and outcome data were collected by independent nurses and researchers who were unaware of the purpose of the study. Patient data were reviewed via electronic medical records.
Statistical analysis
The analysis was performed in two parts. First, analyses were conducted in the crude population. Data are presented as numbers and frequencies for categorical variables and as mean ± SD for continuous variables. For between-group comparisons, the chi-squared test or Fisher's exact test were used for categorical variables, and the independent samples t-test was used for continuous variables. A Kaplan-Meier analysis was performed to calculate the cumulative incidence of clinical outcomes, and differences were assessed using the log-rank test. A multivariate Cox proportional hazards regression model was used to identify independent predictors of MACE. Factors entered into the multivariate model included those with p-values < 0.10 in the univariate analysis, and variables with known prognostic value.
In the second part of the analysis, a propensity-score matched population was selected to adjust for the uneven distribution of baseline characteristics and a 3:1 matched analysis was performed. In brief, propensity scores representing the probabilities of TRI were calculated using a multiple logistic regression model, based on the 11 measured baseline covariates. The adjusted variables were as follows: age, gender, hypertension, diabetes mellitus, dyslipidaemia, chronic kidney disease (CKD), current smoker, history of ischaemic heart disease (IHD), history of peripheral artery disease (PAD), initial diagnosis, and extent of disease. SPSS version 18.0 (SPSS Inc, Chicago, Illinois) and the R programming language, version 2.8.0 (R Foundation for Statistical Computing) were used for all statistical analyses. Two-sided p-values < 0.05 were considered to be statistically significant.
Results
The KOTRI registry included 1 319 consecutive patients with NSTE-ACS from 20 centres who were successfully revascularised using DES from May 2012 to January 2015. Of these patients, 1 285 were eligible for the study and 34 were excluded due to lack of follow-up data. Among them, 983 patients were divided into the TRI group and 302 into the TFI group, according to final vascular access site.
Baseline clinical and angiographic characteristics are shown in Table 1 . Compared with the TFI group, the TRI group had more favourable baseline characteristics, such as lower frequency of diabetes mellitus and CKD, and history of IHD and PAD, except for dyslipidaemia, which was more common in the TRI group. In addition, the TRI group was less likely to initially present with NSTEMI and multi-vessel disease (MVD). Other baseline clinical and angiographic characteristics were not different between the two groups.
The cumulative clinical outcomes in the crude population at one year are presented in Table 2 and Fig. 1 . The rate of MACE was significantly lower in the TRI group than in the TFI group (4.2 vs 7.0%, p = 0.045), which was mainly driven by the lower rate of CD in the TRI group (0.9 vs 2.3%, p = 0.050). However, there were no differences in rates of MI (0.5 vs 0.0%, p = 0.207) and RR (3.3 vs 4.6%, p = 0.247) between two groups at one year.
Bleeding occurred in 27 patients (2.2%) in the crude population and was significantly less frequent in the TRI group than in the TFI group (1.3 vs 5.1%, p < 0.001). This difference was mainly TRI = transradial intervention; TFI = transfemoral intervention; IHD = ischaemic heart disease; PAD = peripheral artery disease; NSTEMI = non-ST-segment elevation myocardial infarction; VD = vessel disease; LAD = left anterior descending artery; LCX = left circumflex artery; RCA = right coronary artery; LM = left main. AFRICA driven by the lower frequency of major bleeding in the TRI group (0.4 vs 3.4%, p < 0.001). However, there was no significant difference in minor bleeding rates between the two groups (0.8 vs 1.7%, p = 0.199) ( Table 3) . To minimise allocation bias and better describe the treatment impact of TRI in NSTE-ACS patients, propensity-score matching was done. After 3:1 propensity-score matching, 624 of 983 patients in the TRI group (63.5%) were successfully matched to 241 patients in the TFI group. The baseline characteristics of the two groups were well balanced after matching (Table 4) .
The clinical outcomes of the matched population were different from those of the crude population (Table 2, Fig. 2 ). The rate of MACE was not different between the TRI and TFI groups (4.0 vs 5.4%, p = 0.333). Also, there were no significant differences in rates of CD, MI and RR between the two groups.
Bleeding complications of the matched population were similar to those of the crude population. Bleeding occurred in 20 patients (2.4%) and was significantly less frequent in the TRI group (1.0 vs 6.0%, p < 0.001), which was mainly attributable to the lower frequency of major bleeding in the TRI group (0.3 vs 3.8%, p < 0.001). However, there was no significant difference in minor bleeding rates between the two groups (0.7 vs 2.1%, p = 0.126) ( Table 3) .
To identify independent predictors of MACE after successful PCI in this registry, Cox proportional hazard regression analysis was performed ( Subgroup analysis regarding MACE was performed according to older age (≥ 65 years), gender, hypertension, diabetes mellitus, dyslipidaemia, CKD, current smoker, history of IHD, history of PAD, presence of NSTEMI and MVD. Results in the various subgroups were similar to those observed in the entire population (Fig. 3 ). There were no significant differences in clinical outcomes between the two groups, and the results were consistent across all subgroups, without any significant interactional p-value.
Discussion
This study examined the role of vascular access site exclusively, in patients with NSTE-ACS undergoing PCI from the KOTRI registry, which is a large, observational cohort to describe the The following variables were considered in the model: TRI, older age (≥ 65 years), gender, hypertension, diabetes mellitus, dyslipidaemia, CKD, current smoking, history of IHD, history of PAD, NSTEMI, multi-vessel disease (2VD or 3VD). TRI = transradial intervention; IHD = ischaemic heart disease; PAD = peripheral artery disease; NSTEMI = non-ST-segment elevation myocardial infarction; VD = vessel disease. association between clinical outcomes and bleeding complications with TRI. The major findings of this analysis are: (1) the TRI group had a lower rate of MACE and CD than the TFI group in the crude population at one-year follow up; (2) there were no significant differences in rate of MACE and CD between the two groups after propensity-score matching; (3) rates of major bleeding complications were lower in the TRI than the TFI group in both the crude and matched populations; (4) CKD and MVD were independent predictors of MACE in patients with NSTE-ACS, suggesting that clinical and angiographic profiles rather than vascular access site are important in determining clinical outcomes after intervention for NSTE-ACS.
The increasing adoption of radial access currently has led to the inevitable debate on preferred vascular access site. Although recent ACCF/AHA/SCAI PCI practice guidelines strongly recommend the radial approach, 13 adoption of radial access for PCI has been variable in different countries. 2 For example, the radial route is predominant in Canada, France and Japan, in contrast to the United States, Germany and India, who mainly use the femoral route. 2 Moreover, there is an incomplete evidence base for overall superiority of the radial approach over the femoral approach.
Recently, two randomised, controlled trials were published regarding clinical outcomes of TRI in patients with ACS. 5, 7 The RIVAL trial showed the clear benefit of TRI in terms of primary outcome (a composite of death, MI, stroke and major bleeding) (HR: 0.60, 95% CI: 0.38-0.94; p = 0.026) and mortality (HR: 0.39, 95% CI: 0.20-0.76; p = 0.006) at 30 days in patients with STEMI.
5 Also in the RIFLE-STEACS study, TRI was associated with significant clinical benefits in the primary outcome (a composite of CD, stroke, MI, TLR and bleeding) (13.6 vs 21.0%, p = 0.003) and cardiac mortality rate (5.2 vs 9.2%, p = 0.020) at 30 days in patients with STEMI, compared with TFI. 7 Consistent with these results, Karrowni et al. concluded from their metaanalysis, including 12 randomised trials, that TRI was associated with favourable outcomes in STEMI patients and should be the preferred approach for experienced radial operators. 5 Post hoc analysis of the EARLY-ACS trial revealed no significant differences in 30-day death/MI (12.6 vs 11.2%, p = 0.162) or 30-day death (1.8 vs 2.3%, p = 0.257) between the TRI and TFI groups. 8 In our study, the rates of 30-day MACE and CD were no different between the TRI and TFI groups (0.8 vs 0.4%, p = 0.545; 0.5 vs 0.0%, p = 0.283, respectively), nor were the rates of one-year MACE and CD. Therefore our data corroborate previous findings and extend the observations to one year.
Regarding bleeding complications, the subgroup analysis of the PRESTO-ACS trial revealed that TRI was associated with a significant decrease in TIMI bleeding (0.7 vs 2.7%, p = 0.03) at one year in patients with NSTE-ACS. 9 Also, subgroup analysis of the RIVAL trial showed lower rate of ACUITY-defined bleeding with TRI in the NSTE-ACS cohort. 5 However, the results in the previous two studies were derived from subgroup analysis, which had the potential for false-positive errors. 15 Furthermore, the former study was conducted without any sensitivity analysis despite uneven distribution of baseline clinical, procedural and pharmacological characteristics between the TRI and TFI groups. 9 Corroborating previous findings, our analysis was in line with earlier results, using different bleeding criteria (BARC criteria) in a significantly larger TRI cohort, although bleeding is an outcome that is definition dependent. 16 Therefore, our study strongly supports the benefit of TRI with regard to bleeding complications in intervention for NSTE-ACS and may be more reflective of real-world clinical practice.
For the paradigm shift from 'femoral access first' to 'radial access first' in the middle of the debate on the preferred vascular access site in PCI, there should be enough clinical evidence supporting the efficacy and safety of TRI to TFI. However, there is an incomplete evidence base for TRI, especially in patients with NSTE-ACS. In this study, we clearly demonstrated that TRI shows comparable one-year clinical outcomes and lower bleeding complications compared to TFI. In addition, for NSTE-ACS patients, more will be on the more potent antiplatelet agents such as prasugrel and ticagrelor, which have higher bleeding risks than clopidogrel. 17, 18 Therefore, TRI might become the vascular access site of choice and the best option to decrease bleeding complications, with favourable clinical outcomes in NSTE-ACS intervention.
Study limitations
This study has several limitations. First, there may have been an allocation bias based on uneven distribution of risk factors and clinical and anatomical conditions of the patients, since this was a non-randomised, observational study and the selection of vascular access site was left to the operator's discretion. To overcome this, we used robust statistical methods, including propensity-score matching and multivariate Cox proportional hazards regression.
Second, we did not account for the cross-over rate and exact reasons for it, since these measures were not fully collected. Third, we were unable to study the impact of the recent improvement in the femoral technique, such as the reduction of endovascular device diameter, early removal of the arterial introducer, and preference for the femoral puncture technique guided by fluoroscopy or ultrasound, which might translate into a lower incidence of vascular complications.
Finally, the rate of bleeding complications may have been low because operators participating in the KOTRI registry were highly experienced in both the radial and femoral approaches. Therefore, our results may not apply to all centres performing radial procedures.
Conclusion
In the large, observational cohort of the KOTRI registry, TRI was associated with favourable one-year clinical outcomes and lower bleeding complications compared to TFI in patients with NSTE-ACS undergoing PCI. Independent predictors of MACE were clinical and angiographic profiles (CKD, MVD) rather than vascular access sites. These data suggest that TRI may be the preferred option in patients with NSTE-ACS.
